Loading
Across 111,080 Galleri tests ordered in ordinary US practice, about one in a hundred was positive, and where doctors reported back, just over half of those people had cancer.
Matrana and colleagues analysed 111,080 people (median age 58) who had the Galleri test commercially. The cancer signal detection rate was 0.91% (1,011 of 111,080). Providers reported a clinical outcome for 459 of the 1,011; 258 of these had an invasive cancer diagnosis across 32 cancer types. Cancer signal origin was correct in 87% of cases with a reported cancer type, and the median time from result to diagnosis was 39.5 days.
Outcomes are known for fewer than half of the positives, so the share of positives that were cancer in this group cannot be read as the test's positive predictive value, and cancers missed by the test are not counted at all.
Shares GRAIL, Positive predictive value (PPV), Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Positive predictive value (PPV), Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/